Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study.

ABSTRACT:

Background

Ketamine is a promising treatment for post-traumatic stress disorder (PTSD), but further research is required to extend early findings.

Aims

To determine the short-term efficacy and tolerability of intramuscular (i.m.) ketamine compared with i.m. fentanyl for treatment-resistant PTSD symptoms.

Method

We completed a randomised double-blind psychoactive-controlled study with single doses of i.m. racemic ketamine 0.5 mg/kg or 1.0 mg/kg or i.m. fentanyl 50 μg (psychoactive control). Eligible participants were aged between 18 and 50 years old and had treatment-refractory PTSD. The primary efficacy measure was the Impact of Events Scale - Revised (IESR), and tolerability was measured with the Clinician-Administered Dissociative States Scale. Analysis of variance

SUBMITTER: Beaglehole B 

PROVIDER: S-EPMC12529321 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature